Published in Women's Health Weekly, August 21st, 2003
Studies were conducted using a targeted formulation of Targeted Genetics' proprietary synthetic, lipid-based gene delivery system called LPD-PEG. Data demonstrate that use of LPD-PEG, along with an additional targeting molecule, delivered systemically resulted in a significant reduction in tumor size and an increase in survival time when compared to non-targeted LPD-PEG in animal models of breast cancer.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.